A novel peptide for a drug delivery system to preferentially target bone formation sites

Bone ◽  
2010 ◽  
Vol 47 ◽  
pp. S413-S414 ◽  
Author(s):  
Heng Wu ◽  
Ge Zhang ◽  
Bao Sheng Guo ◽  
Tang Tao ◽  
Gang Li ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Bone Formation ◽  
Drug Delivery System ◽  
Delivery System

Cell-mediated BMP-2 release from a novel dual-drug delivery system promotes bone formation

2013 ◽  
Vol 25 (12) ◽  
pp. 1412-1421 ◽  
Author(s):  
Tie Liu ◽  
Gang Wu ◽  
Yuanna Zheng ◽  
Daniel Wismeijer ◽  
Vincent Everts ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Bone Formation ◽  
Drug Delivery System ◽  
Delivery System ◽  
Dual Drug

Simvastatin-Loaded β-TCP Drug Delivery System Induces Bone Formation and Prevents Rhabdomyolysis in OVX Mice

2012 ◽  
Vol 2 (5) ◽  
pp. 678-681 ◽  
Author(s):  
Joshua Chou ◽  
Tomoko Ito ◽  
Makoto Otsuka ◽  
Besim Ben-Nissan ◽  
Bruce Milthorpe
Keyword(s):  
Drug Delivery ◽  
Bone Formation ◽  
Drug Delivery System ◽  
Delivery System

Hexosomes based on cholesterol and phosphatidylcholine: a new drug delivery system for curcumin release

Planta Medica ◽  
2015 ◽  
Vol 81 (16) ◽  
Author(s):  
AR Bilia ◽  
G Capecchi ◽  
MC Salvatici ◽  
B Isacchi ◽  
MC Bergonzi
Keyword(s):  
Drug Delivery ◽  
Drug Delivery System ◽  
Delivery System ◽  
New Drug

Development and Evaluation of Floating Pulsatile Drug Delivery System Using Meloxicam

2017 ◽  
Vol 7 (04) ◽  
Author(s):  
ShirishaG. Suddala ◽  
S. K. Sahoo ◽  
M. R. Yamsani
Keyword(s):  
Rheumatoid Arthritis ◽  
Drug Delivery ◽  
Drug Release ◽  
Drug Delivery System ◽  
Delivery System ◽  
Lag Time ◽  
Oral Dosage ◽  
Lag Phase ◽  
Pulsatile Drug Delivery

Objective: The objective of this research work was to develop and evaluate the floating– pulsatile drug delivery system (FPDDS) of meloxicam intended for Chrono pharmacotherapy of rheumatoid arthritis. Methods: The system consisting of drug containing core, coated with hydrophilic erodible polymer, which is responsible for a lag phase for pulsatile release, top cover buoyant layer was prepared with HPMC K4M and sodium bicarbonate, provides buoyancy to increase retention of the oral dosage form in the stomach. Meloxicam is a COX-2 inhibitor used to treat joint diseases such as osteoarthritis and rheumatoid arthritis. For rheumatoid arthritis Chrono pharmacotherapy has been recommended to ensure that the highest blood levels of the drug coincide with peak pain and stiffness. Result and discussion: The prepared tablets were characterized and found to exhibit satisfactory physico-chemical characteristics. Hence, the main objective of present work is to formulate FPDDS of meloxicam in order to achieve drug release after pre-determined lag phase. Developed formulations were evaluated for in vitro drug release studies, water uptake and erosion studies, floating behaviour and in vivo radiology studies. Results showed that a certain lag time before drug release which was due to the erosion of the hydrophilic erodible polymer. The lag time clearly depends on the type and amount of hydrophilic polymer which was applied on the inner cores. Floating time and floating lag time was controlled by quantity and composition of buoyant layer. In vivo radiology studies point out the capability of the system of longer residence time of the tablets in the gastric region and releasing the drug after a programmed lag time. Conclusion: The optimized formulation of the developed system provided a lag phase while showing the gastroretension followed by pulsatile drug release that would be beneficial for chronotherapy of rheumatoid arthritis and osteoarthritis.

Sign in / Sign up

Export Citation Format

Share Document